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Poster Session I 55donor type, conditioning regimen, and frequency of second trans-
plants between patients who did or did not return for the 1 year eval-
uation. Among the 106 (90%) patients who had no prior evidence of
recurrent malignancy after HCT, 4 (4%) were diagnosed with re-
current malignancy during the LTFU visit. Among the 31 (26%)
patients had no prior diagnosis of chronic GVHD, 9 (29%) were di-
agnosed with chronic GVHD during the LTFU visit. The table
shows the overall prevalence of abnormal findings and the types
of clinical recommendations documented in letters to the referring
physician. Most patients were immunized during the LTFU visit.
Pre-immunization titers were protective against pneumococcus in
55% of patients, haemophilus influenza B in 21%, tetanus in 36%
and hepatitis B in 26%; 95% required additional doses of at least
one vaccine. Bone and lipid abnormalities and absence of protective
antibody titers to pneumococcus, haemophilus, tetanus and hepati-
tis B were not associated with current or previous history of chronic
GVHD, current use of steroids or calcineurin inhibitors or number
of immunosuppressive agents, suggesting that all patients should be
tested. We conclude that routine comprehensive LTFU evaluation
at one year after allogeneic HCT detects a high frequency of med-
ical problems requiring active intervention or adjustment of ther-
apy. While the ultimate effect on health outcomes is unknown,
our experience suggests that systematic evaluation at one year after
HCT is an important part of monitoring for late effects.
Prevalence of problems and frequencies of recommendations
Recommendations*Problem PrevalenceContinuation
of current
managementDose change
or new
medicationsActive chronic GVHD 64% 19% 79%Abnormal iron studies 71% 26% 15%Elevated fasting lipids 56% 21% 18%Abnormal thyroid tests 22% 52% 16%Osteopenia 1 osteoporosis 52% 1 6% 42% 44%*Among patients with problem.Impact of Insurance Coverage
Insurance
Approval,
Days
Time to
Transplant,
Days
N Median Mean Range Median Mean Range
Insurance
Coverage
24 41 53 0–155 106 119 13–346
Insurance
Limitations
9 93 130 22–275 218 240 109–497
*Restrictions 4 68 81 22–168 232 268 109–497
*No Coverage 5 174 169 90–275 218 219 128–371145
REDUCED INTENSITY CONDITIONING (RIC) IS ASSOCIATED WITH
SHORTER DURATION OF CHRONIC GVHD THAN MYELOABLATIVE CON-
DITIONING AND PROVIDES VERY GOOD QUALITY OF LIFE FOR LONG-
TERM SURVIVORS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
Shimoni, A., Hardan, I., Shem-Tov, N., Rand, A., Ribakovsky, E.,
Yerushalmi, R., Nagler, A. Chaim Sheba Medical Center, Tel-
Hashomer, Israel.
RIC has been increasingly used over the last decade in patients
(pts) not eligible for myeloablative conditioning (MC). RIC allows
consistent engraftment with reduced toxicity, yet the long-term ef-
fects, the duration of immunosuppressive therapy (IST) and quality
of life in long-term survivors are less defined. We compared out-
comes of 48 pts given RIC to 41 pts given MC from 1/2000 to 8/
2002. The median age was 49 (range, 20–65) and 37 (20–65) years
in the RIC andMC groups, respectively (p5 0.01). The MC group
included more pts with acute leukemia/MDS (68% vs 33%, p 5
0.001) while pts with myeloma were given only RIC (31% of the
RIC group, p\ 0.001). 48% of pts in the RIC and none in the
MC group had a prior autologous SCT (p\0.001). After a median
follow-up of 6.1 years (range, 5.1–7.6) 40 pts are alive, 20 after RIC
and 20 after MC with estimated survival of 42% (95 ci, 28–56) and
47% (95 ci, 31–63), respectively (p5NS). Long-term survival with
RIC was achieved across all diagnoses including 6 of 16 pts with
acute leukemia/MDS, 6 of 6 pts with CML, 3 of 11 pts with lym-
phoid malignancies and 5 of 15 pts with myeloma. The correspond-
ing rates in the MC group were 13 of 28, 3 of 4, 4 of 9, and 0 of 0,
respectively. Chronic GVHD occurred in 22 pts after RIC [cumu-
lative incidence 48%(35–65)] and in 26 pts after MC [66%(53–83),
(p 5 0.07)]. 12 pts with chronic GVHD after RIC were eventually
able to stop IST, 9 died on IST (relapse-5, non-relapse-4) and only1 of 20 long-term survivors was still on IST at last follow-up. The
median duration of IST was 17 months and the probability of stop-
ping IST after 5 years was 79%. In the MC group 10 pts with
chronic GVHD were able to stop IST, 8 died on IST (relapse-6,
non-relapse-2) and 8 of 20 long-term survivors were still on IST
at last follow-up. The median duration of IST was 41 months (p
5 0.05) and the probability of stopping IST after 5 years was
48% (p 5 0.001). Two women gave birth in the RIC group while
2 men in the MC group fathered children spontaneously. There
was one secondary malignancy in the MC group and 2 pts sustained
myocardial infarction (one fatal). One pt in the RIC group had re-
versible nephrotic syndrome. In summary long term survival is sim-
ilar after RIC and MC SCT, however IST is significantly shorter
after RIC. All 20 pts survivingmore than 5 years after RIC sustained
excellent quality of life and only one still required IST.These obser-
vations require further confirmation in larger registry studies.146
IMPACT OF HEALTH INSURANCE ON TIME TO APPROVAL AND TIME TO
TRANSPLANT AMONG PATIENTS RECEIVING HEMATOPOIETIC STEM
CELL TRANSPLANTATION
McHenry, M., Hayes-Lattin, B., Maziarz, R.T. Oregon Health and Sci-
ence University, Portland, OR.
Access to hematopoietic stem cell transplantation (HSCT),
a therapy that can be curative for patients with various life-threaten-
ing disorders, is often limited by a patient’s health insurance cover-
age. It is difficult to quantitate the impact of health insurance on
referrals to a transplant center, and health insurance status may be
one of several reasons for not undergoing HSCT after an initial
consultation. However, we hypothesize that even among patients
who receive HSCT, insurance coverage influences the timing of
transplant.We retrospectively analyzed the time to obtaining insur-
ance approval and to proceeding to HSCT based on insurance sta-
tus for that type of procedure at the time of the initial consultation.
During the first quarter of 2006, 16 patients proceeded to autolo-
gous and 17 proceeded to allogeneic HSCT. Patients were catego-
rized as having an insurance plan that covered their transplant or
that had limitations. Limitations included either no coverage or in-
surance restrictions, such as initial denial requiring an appeal, no
coverage for HLA-typing or search, or a waiting period. More
than 25% of patients receiving either autologous or allogeneic
HSCT experienced limitations imposed by their health insurance
coverage. The median time to insurance approval (41 versus 93
days) and the median time to transplant (106 versus 218 days) was
more than twice as long for those with limitations imposed by their
insurance plan. Patients who initially had no transplant coverage
ultimately received their transplant earlier than those with other
restrictions, by either changing insurance plans or paying out-of-
pocket. A complete analysis of 2006 will be updated at the time of
presentation. This method of analysis undoubtedly underestimates
the true impact of insurance coverage. Patients who have delaysmay
experience disease relapse or other morbidity during that delay
which precludes proceeding to HSCT. Even among those patients
who were referred to our transplant center and received HSCT,
the covered transplant may not have followed the initial
56 Poster Session Irecommendation. This includes patients who received only one of
a recommended tandem autologous HSCT, or who received an au-
tologous rather than a recommended allogeneic procedure. But
given the limitations of this analysis, we conclude that restrictions
imposed by health insurance coverage lead to significant delays in
implementing the treatment plan for patients who receive HSCT.147
MEASURING THE SYMPTOM BURDENOF CHRONIC GRAFT VERSUS HOST
DISEASE
Williams, L.A.1, Neumann, J.L.2, Couriel, D.R.3, Mendoza, T.R.1,
White, M.H.1, Zhang, Y.1, Cleeland, C.S.1 1The University of Texas
MD Anderson Cancer Center, Houston, TX; 2The University of Texas
MD Anderson Cancer Center, Houston, TX; 3Sarah Cannon Cancer
Center and Tennessee Oncology, Nashville, TN.
Significance: Chronic graft-versus-host disease (cGVHD) is an
autoimmune-like reaction that causes debilitating symptoms fol-
lowing allogeneic hematopoietic stem cell transplantation (al-
loHSCT). The major barrier to good management of these
symptoms is inadequate assessment. Theoretical Framework:
Symptom burden is the combined impact of all symptoms on a per-
son’s ability to function as one did prior to onset of disease and ther-
apy.Problem andPurpose:There is scant literature addressing the
symptom burden of cGVHD. Symptoms are subjective phenomena
and can only be accurately measured by patient report. The pur-
poses of this research are to develop a short, easily understood, valid,
and reliable patient questionnaire for measuring cGVHD symptom
burden and to describe the symptom burden of cGHVD. This ab-
stract reports preliminary results.Methods: The 13 core symptom
items and 6 interference items of the M. D. Anderson Symptom In-
ventory (MDASI), rated on a scale of 0 to 10, are the base for the
MDASI-GVH. In addition, 14 cGVHD-specific symptom items
were generated from interviews with patients and the ratings of an
expert panel. 128 patients with cGVHD and 64 patients post al-
loHSCTwithout cGVHDwill complete the MDASI-GVH. Infor-
mation on performance status, quality of life, and a repeat MDASI
will be collected on patients with cGVHD. Psychometric analyses
will reduce the number of items to the optimal set describing symp-
tom burden, determine predictive and discriminant validity, and es-
tablish internal consistency and test-retest reliability. The symptom
burden of cGVHD will be described through descriptive, correla-
tional, cluster, and factor analyses. Results: To date, 31 patients
with cGVHD and 7 without have completed the MDASI-GVH.
Average age is 49.3 years and 50% are male. Symptom severity
and interference is displayed in Table 1. Patients with cGVHD re-
ported a unique cluster of severe symptoms that included skin prob-
lems, eye problems, muscle weakness, and joint stiffness. By
February of 2008, we will report data on 45 patients with cGVHD
and 20 patients without cGVHD. Implications: Patients with
cGVHD tend to report more symptom severity and interference
than patients post alloHSCT without cGVHD. The most severe
symptoms patients with cGVHD report are cGVHD-specific. Fur-
ther testing is ongoing, but the MDASI-GVH is an easily com-
pleted method of quantifying symptoms of cGVHD for clinician
monitoring and use in trials testing methods to treat cGVHD.
Table 1. Symptom Severity and Interference in Patients With and
Without cGVHD
cGVHD No cGVHDItem Mean SD Mean SDSeverity of 13
Core Symptoms1.91 1.41 1.45 1.40Severity of 14 cGVHD-
Specific Symptoms2.24 1.41 1.53 0.87Severity of All Symptom 2.05 1.33 1.49 1.05
Symptom Interference 2.80 2.19 2.60 1.75SD 5 standard deviation.148
LONG-TERM NEUROCOGNITIVE FUNCTION OF PEDIATRIC PATIENTS
WITH SEVERE COMBINED IMMUNE DEFICIENCY (SCID): PRE AND
POST HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
Lin, M.1, Epport, K.2, Azen, C.2, Shah, A.J.3 1Keck School of Medicine,
Los Angeles, CA; 2Childrens Hospital Los Angeles, Los Angeles, CA;
3Childrens Hospital Los Angeles, Los Angeles, CA.
Background: Hematopoietic stem cell transplantation (HSCT)
is the only cure for patients with severe combined immunodefi-
ciency (SCID). The purpose of this study is to evaluate long-term
neurocognitive function of patients with SCID following myeloa-
blative chemotherapy and HSCT. Materials and Methods: Six-
teen pediatric patients diagnosed with SCID were tested using the
Bayley Scales of Infant Development and the validated Vineland
Adaptive Behavior Scales (VABS) pre- and 1-year post-HSCT.
Three years post HSCT there were 11 patients available for testing
and four patients were available 5 years post-HSCT. Patients
greater than 3 years of age were administered the Wechsler Pre-
school and Primary Scale of Intelligence (WPPSI). Both raw scores
and scaled scores were analyzed. Data were analyzed using multiple
regression analysis.Results:Therewas a significant decrease 1-year
post-HSCT in the Bayley Mental Developmental Index (MDI)
[92.5 (pre) vs. 70.8 (1 yr post); p5\0.0001] and the VABS [99.73
(pre) vs. 79.87 (1 year post), p5\0.0001]. There was no change
in the Bayley Psychomotor Development Scale (PDI) [82.4 (pre)
vs. 84.8 (1 year post), p 5 0.68]. There was a significant decrease
over time in the MDI [95.00 (pre) vs. 70.4 (1-year post) vs. 69.20
(3 yr post); p\ 0.0001), but no significant change between 1- and
3-years post- HSCT]. The PDI scores decreased over time [86.29
(pre) vs. 86 (1-year post) vs. 74.14 (3-years post), p 5 0.045]. Al-
though there was a decrease in scaled scores, there was not a loss
of skills. Analysis of raw scores showed that there was an increase
in the raw test scores, which indicated that these children acquired
developmental skills, but at a slower rate than normal infants and
toddlers. Conclusions: These findings may reflect the effects of
the isolation and prolonged hospitalization that characterizes the
immediate post transplant period. Patients miss out on social inter-
actions and learning opportunities that normally occur at their re-
spective stages of development. These restrictions keep patients
from acquiring developmentally appropriate cognitive skills as
well as gross and fine motor developmental milestones. Longitudi-
nal follow-up will be important to quantify acquisition of skills.LEUKEMIA149
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (Allo-HCT)
FOR PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC
LEUKEMIAS: IMPACT OF IMATINIB ON RISK OF RELAPSE AND SURVIVAL
Burke, M.J.1, Trotz, B.1, Luo, X.2, DeFor, T.E.2, Burns, L.J.3,
Baker, K.S.1,Weisdorf, D.J.3,Wagner, J.E.1, Verneris, M.R.1 1Univer-
sity of Minnesota, Minneapolis, MN; 2University of Minnesota, Minne-
apolis, MN; 3University of Minnesota, Minneapolis, MN.
The utility of Imatinib use in either the pre-or-post-transplant
period for Philadelphia positive (Ph1) Acute Lymphoblastic Leu-
kemia (ALL) is unknown. Additionally, there have been concerns
regarding Imatinib and cardiac toxicity (congestive heart failure)
in some series. Therefore, we investigated the outcome of trans-
plantation in patients with Ph1 ALL and treated with Imatinib.
Thirty-two patients with Ph1 ALL received allo-HCT at the Uni-
versity of Minnesota between 1999 and 2006. The median age at
HCT was 21.9 (range; 2.8–55.2) years. Eighteen (56.3%) patients
were male. Twenty patients were in first remission (CR1) prior to
HCT and 12-patients were in second remission (CR2). Donor
source was HLA matched and mismatched unrelated umbilical
cord blood (n 5 17), HLA matched sibling bone marrow (n 5 12)
and HLA matched unrelated bone marrow (n 5 3). All patients
were conditioned with cyclophosphamide and total body irradia-
tion. GVHD prophylaxis was with CSA/MTX (n 5 15), CSA/
MMF (n 5 13) or CSA methylprednisone/ATG (n 5 4). Of the
32 patients with Ph1 ALL, fifteen received Imatinib therapy pre/
